Quantifies the BCR/ABL1 p210 fusion transcript using real-time quantitative reverse-transcription PCR.
Used primarily to establish a baseline and monitor treatment response in people with a known BCR/ABL1 p210-positive condition, particularly chronic myeloid leukaemia. It is not designed to detect or monitor the p190 fusion form.